Defendant Name: Emergent BioSolutions, Inc.

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 29089Q10

Initial Case Details

Legal Case Name In the Matter of Emergent BioSolutions, Inc.
First Document Date 07-Apr-2025
Initial Filing Format Administrative Action
File Number 3-22472
Allegation Type Issuer Reporting and Disclosure

Violations Alleged

Securities Act
• Sec 17(a)(2)

Resolutions

First Resolution Date 07-Apr-2025
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

33-11371 07-Apr-2025 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933, Making Findings, and Imposing a Cease-and-Desist Order
On April 7, 2025, the SEC instituted cease-and-desist proceedings against Emergent BioSolutions, Inc., stating: "This proceeding arises out of violations of Section 17(a)(2) of the Securities Act by Emergent. From at least April 2020 to April 2021 (“relevant period”), Emergent made a series of materially misleading public statements touting Emergent’s ability and readiness to manufacture COVID-19 vaccine doses at its Bayview facility (“Bayview”) in Baltimore, Maryland, while omitting information about issues in the state of readiness of its facilities, personnel training, and quality control protocols to implement its contracted manufacturers’ COVID-19 vaccine manufacturing processes."